Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Abstract
Summary We report a case of a 38-year-old woman who was diagnosed with stage IV lung adenocarcinoma, harboring an epidermal growth factor receptor ( EGFR ) L858R mutation on exon 21 and a T790 M mutation on exon 20. The patient was treated with osimertinib, a third-generation EGFR tyrosine kinase inhibitor ( EGFR -TKI) following treatment with nivolumab, an anti-Programmed Cell Death 1 (anti-PD1) antibody. After initiating osimertinib treatment,...
Paper Details
Title
Osimertinib-induced interstitial lung disease after treatment with anti-PD1 antibody
Published Date
Sep 6, 2016
Journal
Volume
35
Issue
1
Pages
105 - 107
Citation AnalysisPro
You’ll need to upgrade your plan to Pro
Looking to understand the true influence of a researcher’s work across journals & affiliations?
- Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
- Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.
Notes
History